What are the primary FDA approval pathways for drugs, biologics, and medical devices?

The FDA uses different approval routes depending on the product. Drugs typically move through an IND followed by an NDA, while biologics progress through an IND and then a BLA due to their complexity. Medical devices are regulated based on risk and may require 510(k) clearance, De Novo classification, or Premarket Approval. Knowing the right pathway early helps streamline development.

What strategic elements play the biggest role in achieving FDA approval?

Success with the FDA depends on early regulatory planning, frequent communication with the agency, a clear Target Product Profile, strong manufacturing controls, and well-prepared clinical and nonclinical strategies. Companies that take a proactive approach generally face fewer regulatory challenges.

How is the regulatory evaluation of biologics different from that of traditional small-molecule drugs?

Biologics are derived from living systems and are more sensitive to manufacturing changes. Their regulatory pathway usually involves a BLA and requires extensive analytical, clinical, and quality data. In contrast, small-molecule drugs follow the NDA pathway and rely more on chemical characterization and controlled synthesis.

What challenges do companies commonly face when navigating FDA approval?

Common challenges include unclear regulatory pathways, inadequate manufacturing readiness, insufficient clinical planning, delayed FDA engagement, and lack of preparedness for inspections or global regulatory coordination. These issues often lead to delays or additional information requests.

In what ways does the roadmap to FDA approval differ between drug and device development?

While both involve preclinical work, human studies, submission, and post-market activities, their requirements differ greatly. Drug and biologic programs emphasize clinical trials and detailed CMC data. Devices may focus more on engineering testing, software validation, and human factors, and may rely on predicate devices for 510(k) submissions.

FDA eConsent Compliance: Building a Participant-Centric Informed Consent Process

The increasing use of electronic informed consent is reshaping how sponsors and investigators conduct informed consent in FDA-regulated clinical research. Digital platforms can improve access to study information, support participant engagement, and facilitate remote consent activities. However, electronic implementation does not reduce regulatory responsibilities. Sponsors must ensure that the consent process, electronic records, system controls, and participant experience remain consistent with applicable FDA requirements and clinical research standards. Electronic systems used in regulated clinical investigations introduce additional compliance considerations. 21 CFR Part 11 compliance is particularly relevant when electronic records and electronic signatures are used in FDA-regulated activities. Part 11 establishes criteria under which electronic records and electronic signatures may be considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. Sponsors should therefore evaluate whether their eConsent technology and associated controls appropriately address system access, electronic signatures, audit trails, record protection, and data integrity.

FDA’s October 2024 guidance, “Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers,” provides updated recommendations for the use of electronic systems and records in clinical investigations. The guidance emphasizes the importance of reliable systems and trustworthy records that allow study activities and data to be appropriately reconstructed. This makes technology qualification, validation, documented procedures, and appropriate oversight important elements of an effective eConsent program. The regulatory assessment should extend beyond the software itself. Sponsors need to evaluate the complete consent workflow, including how participants receive information, how investigators interact with participants, how consent decisions are documented, and how records are maintained. A vendor may provide a technically capable platform, but the sponsor remains responsible for ensuring that the system is used appropriately within the clinical investigation. Vendor qualification, contractual responsibilities, change control, training, and ongoing oversight should therefore form part of the overall governance strategy.

eConsent in clinical trials can also support a more participant-centric approach to informed consent. Conventional consent documents can contain complex scientific and medical information that may be difficult for participants to understand. Electronic platforms can incorporate plain-language explanations, visual aids, multimedia presentations, and other appropriate features that may help participants engage with study information. However, these features should enhance comprehension rather than simply make the consent experience more technologically sophisticated. Participant-centricity should remain focused on meaningful decision-making. Sponsors should consider accessibility, language needs, health literacy, technology familiarity, and the ability of participants to access and use the electronic system. Where technology creates barriers rather than reducing them, alternative processes or appropriate accommodations may be necessary. The goal should be to help participants understand the study, its potential risks and benefits, their responsibilities, and their rights before making a voluntary decision.

FDA and other regulatory stakeholders have continued to emphasize informed consent quality and participant understanding. FDA’s March 2024 draft guidance on key information and facilitating understanding of informed consent reflects the agency’s focus on making essential study information understandable to prospective participants. This reinforces the importance of designing digital consent experiences around comprehension and informed decision-making rather than treating electronic signature collection as the primary objective. Compliance risks can arise when organizations focus heavily on the technology while overlooking the underlying regulated process. Common concerns include inadequate system validation, incomplete audit trails, inappropriate user access, weak authentication controls, failure to maintain approved consent versions, insufficient documentation of consent timing, inadequate training, and ineffective vendor oversight. Problems involving amended consent forms can be particularly significant because sponsors must be able to demonstrate which version was presented and when participant consent was obtained.

Data integrity is another critical consideration. Electronic consent records should be protected against unauthorized alteration and retained in accordance with applicable requirements and study procedures. Organizations should have documented processes for maintaining records, managing system changes, handling deviations, and responding to potential data integrity issues. These controls can become particularly important during regulatory inspections, when sponsors may need to demonstrate that consent records are complete, reliable, attributable, and appropriately maintained. A practical implementation strategy begins with process mapping. Sponsors should document each stage of the consent lifecycle, from participant presentation and review of study information through electronic signature, documentation, amendments, withdrawal, and record retention. The organization can then perform a risk assessment of the technology and workflow, identify applicable regulatory requirements, establish validation activities, define user responsibilities, and develop procedures for training and oversight.

An effective eConsent program should also integrate IRB considerations into implementation planning. The consent content, participant-facing process, and relevant technological features should be submitted for appropriate IRB review and approval before use, consistent with applicable requirements. Any subsequent changes to approved consent materials or processes should be managed through established change-control and IRB procedures.Ultimately, electronic consent should not be viewed simply as a paperless alternative. Properly implemented, it can support more accessible participant communication, standardized documentation, decentralized research models, and operational efficiency while maintaining regulatory safeguards. The technology, however, must remain subordinate to the fundamental purpose of informed consent: ensuring that participants receive understandable information and voluntarily decide whether to participate.

Electronic informed consent can modernize clinical research by supporting participant understanding and operational efficiency. FDA expectations extend beyond electronic signatures to informed consent quality, reliable electronic records, system controls, and oversight. A risk-based, participant-centric approach helps sponsors strengthen compliance and maintain inspection-ready consent processes.

Frequently Asked Questions

1. What FDA considerations should sponsors address when implementing eConsent in a clinical investigation?

Sponsors should evaluate whether the electronic consent process satisfies applicable informed consent requirements under 21 CFR Part 50 and supports participant understanding. The assessment should also address electronic records, electronic signatures, system controls, documentation, record retention, and approp

2. When does 21 CFR Part 11 apply to an electronic informed consent system?

Part 11 may apply when electronic records and electronic signatures are created, modified, maintained, archived, retrieved, or transmitted under FDA regulatory requirements. Sponsors should determine the system’s regulatory scope and implement appropriate controls for security, access, audit trails, validation, and record integrity.

3. What should sponsors evaluate when qualifying an eConsent platform for FDA-regulated research?

Platform qualification should consider intended use, validation, access controls, audit-trail functionality, electronic signature controls, data integrity, record retention, security, system changes, and vendor oversight. Sponsors should also establish documented procedures demonstrating that the technology remains suitable for its intended clinical research purpose.

4. How should participant-centricity be incorporated into an FDA-compliant eConsent process?

Participant-centric eConsent should facilitate comprehension rather than simply digitize the consent form. Sponsors should consider plain-language content, key information, appropriate multimedia, accessibility, language needs, and participant interaction while ensuring that essential regulatory information remains complete and understandable.

5. What eConsent deficiencies could create regulatory or inspection-readiness concerns?

Potential deficiencies include inadequate system validation, incomplete or unreliable audit trails, inappropriate user access, poor control of consent versions, insufficient documentation of the consent process, inadequate training, weak vendor oversight, and failures to appropriately manage changes to approved consent materials. These weaknesses can affect the reliability of consent documentation and the overall integrity of the clinical investigation.